For the quarter ended June 2026, Axsome Therapeutics (AXSM) reported revenue of $218.38 million, up 45.5% over the same period last year. EPS came in at -$0.99, compared to -$0.92 in the year-ago quarter. The reported revenue represents a surprise of -2.74% over the Zacks Consensus Estimate of $224.52 million. With the consensus EPS estimate being -$0.99, the company has not delivered EPS surprise. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, up 46% from a year earlier, as sales of AUVELITY and SUNOSI increased and prescription demand for SYMBRAVO continued to build. The company posted a net loss of $51.3 million, or $0.99 per share, compared with a net loss of $48 million, or $0.97 per share, in the second quarter of 2025. Axsome ended the quarter with approximately $320 million in cash and cash equivalents, versus $323 million at the end of 2025. ...

Axsome Therapeutics (NasdaqGM:AXSM) Q2 2026 Earnings call August 10, 2026 08:00 AM ET Company Participants Ashley Dong Thank you. Good morning, everyone, and welcome to Axsome's second quarter 2026 earnings conference call. Joining me today to discuss our results for the quarter are Dr. Herriot Tabuteau, Chief Executive Officer, Nick Pizzie, Chief Financial Officer, and Ari Maizel, Chief Commercial Officer, who will begin our call with prepared remarks. Mark Jacobson, our Chief Operating Officer, and Hunter ...

Axsome Therapeutics (NasdaqGM:AXSM) Q2 2026 Earnings call August 10, 2026 08:00 AM ET Company Participants Ashley Dong - Senior Director of Investor Relations Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Leonid Timashev - Director of Equity Research Malcolm Hoffman - VP of Equity Research Ash Verma - Executive Director Rudy Li - Director of Equity Research Ami Fadia - Managing Director Matt Barcus - VP of Equity Research Pete Stavropoulos - Director of Equity Research Ram S ...

Axsome Therapeutics (NasdaqGM:AXSM) Q2 2026 Earnings call August 10, 2026 08:00 AM ET Speaker0Good morning, and welcome to the Axsome Therapeutics second quarter 2026 earnings conference call. My name is Kevin. I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, there'll be a question and answer session, and instructions will be given at that time. Please note this call is being recorded. I would now like to hand the call over to Ashley Dong, Senior Direc ...

2Q 2026 Financial Results August 10, 2026 © Axsome Therapeutics, Inc. Forward looking statements & safe harbor Certain matters discussed in this presentation are "forward-looking statements" . The Company may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward- looking statements . In ...

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI 2Q 2026 net product revenue of $35.8 million, representing 20% year-over-year growth SYMBRAVO 2Q 2026 net product sales of $2.3 million AUVELITY launched for treatment of agitation associated with dementia due to Alzheimer's disease in June 2026 NDA submission for AXS-12 for cataplexy in narcolepsy accepted by the FDA ...